The first hours of life carry a profound responsibility to protect, a duty underscored by the World Health Organization

A recent development in West Africa has brought renewed global attention to one of the simplest yet most powerful tools in preventing childhood illness and death: vaccination at birth. The debate follows concerns raised by the World Health Organization over a proposed clinical trial involving the hepatitis B birth dose vaccine in Guinea-Bissau. At its heart, it is a conversation about ethics, equity, and the responsibility to protect the most vulnerable from preventable disease.

Hepatitis B remains a major global health threat, causing hundreds of thousands of deaths each year through chronic liver disease, cirrhosis, and liver cancer. The virus is especially dangerous when transmitted from mother to child during childbirth. Nearly 90 percent of infants infected at birth go on to develop lifelong chronic infection, placing them at high risk of severe complications later in life. This makes the first 24 hours after birth a critical window for intervention.

For more than three decades, the hepatitis B birth dose vaccine has proven to be safe, effective, and lifesaving. Used in over 115 countries, it prevents between 70 and 95 percent of mother-to-child transmission when administered promptly. It is widely recognized as a cornerstone of efforts to eliminate hepatitis B worldwide. Protecting newborns at birth does not only safeguard individual children; it strengthens national health systems and reduces the long-term burden of disease.

The proposed trial raised concerns because it appeared to include withholding this proven vaccine from some newborns in order to study outcomes. Public health experts have cautioned that when an intervention is already known to be effective, denying it to participants can expose them to avoidable harm. Ethical medical research requires that participants are not placed at unnecessary risk, especially when dealing with infants who cannot consent and rely entirely on health systems for protection.

This issue is particularly sensitive in countries facing high disease prevalence. In Guinea-Bissau, more than 12 percent of adults are estimated to be living with chronic hepatitis B, and infection rates among young children remain far above global elimination targets. The country has already taken an important policy step by deciding to introduce the hepatitis B birth dose into its national immunization schedule, with plans for rollout in the coming years. That decision reflects recognition of the vaccine’s value and the urgent need to expand access.

The broader lesson extends beyond one country or one study. Across many low- and middle-income settings, limited resources, gaps in cold-chain systems, and challenges in reaching babies born outside health facilities can delay access to timely vaccination. These structural barriers must be addressed through stronger antenatal screening, trained health workers, improved logistics, and community awareness so that every child receives protection within the first day of life.

Health equity demands that scientific progress never comes at the cost of withholding known, lifesaving care. Instead, research should focus on improving delivery, expanding coverage, and ensuring that innovations reach those who need them most.

As global health partners continue to work with national authorities, this moment should serve as a reminder that prevention begins at birth. When a safe and effective solution already exists, the priority must be to deliver it faster, more fairly, and to every newborn, everywhere.

Source: WHO